

# **Daily Market Review**

Market closed positive 20-Jul-2025

DSEX WENT UP BY 61.6 POINTS


Market closed positive today with decrease in turnover.

Broad index DSEX went up by 61.6 points.


Cement, NBFI and Fuel & Power are the top three sectors that closed positive today while G. Insurance, Mutual Fund and Jute are the top three sectors that closed negative today.

Turnover decreased by 1.7% to BDT 7,759mn (USD 63mn).

Pharma sector dominated the turnover chart covering 16.9% of the total turnover.







 Whee	~~	4	 (al.)				·		7,0 6,0 5,0 4,0 3,0 2,0 1,0 0	00 00 00 00
11 de 1	~~,,	4 							5,0 4,0 3,0 2,0 1,0	00 00 00 00
المر		P4.	اداما	ulk					4,0 3,0 2,0 1,0	00 00 00
ntha		hr.	اماما	υŅ		<b>A.</b>			3,0 2,0 1,0	00 00
		4	10	ulk		A.J	<b>L</b>	M	1,0	
	4 4	4	10							
		4								
20-Aug-24 20-Sep-24	4 4	-5	Ÿ	-55	20-Mar-25	20-Apr-25	-25	20-Jun-25	20-Jul-25	
Aug Sep	oct 6v	Sec	Jan	-e-	ā	Αp	đa,	Ę	Ē	
20-Aug-24 20-Sep-24	20-Oct-24 20-Nov-24	20-Dec-24	20-Jan-25	20-1	20-1	20-	20-May-25	20-	20	
							14			
	BDT mn\/I	HS)			- DSE	X (RI	HS)			
c				over (BDT mn)(LHS)						

Index					
Particulars	Value	△ Points	Dally ∆ %	Dec'24 Value	YTD ∆ %
DSEX	5,194.03	61.6	1.20%	5,216.44	-0.43%
DS30	1,978.73	42.1	2.17%	1,939.73	2.01%
DSES	1,137.16	17.4	1.55%	1,168.90	-2.72%
S&P 500	6,296.79	(0.6)	-0.01%	5,881.63	7.06%
Nikkei 225	39,819.11	(82.1)	-0.21%	39,894.54	-0.19%
FTSE 100	8,992.12	19.5	0.22%	8,132.56	10.57%

Market Statistics Particulars	Today	Last Day	Dally A	Dally Δ %	60 Day MA
Turnover (BDT mn)	7,759	7,897	-138	-1.74%	3,993
Turnover (USD mn)	63	64	-1	-1.74%	33
Volume (mn)	278	295	-18	-6.05%	173
Market Cap (BDT bn)	6,919	6,875	44	0.64%	
Market Cap (USD bn)	56	56	0	0.64%	
Market P/E (x)	11.2				
Particulars	Galner	Loser	Unchanged		
Market Breadth	180	146	72		

Sector	Market Cap	% of total	Sector	Turnover (BDTmn)	% of
	(BDTmn)	Market Cap	Return		total Turnover
Bank	694,497	19.96%	0.3%	934.2	12.04%
Telecom	569,380	16.36%	1.1%	156.3	2.01%
Pharma	555,908	15.97%	1.8%	1,308.6	16.87%
Fuel & Power	303,533	8.72%	3.0%	493.9	6.37%
Engineering	276,370	7.94%	1.7%	631.2	8.13%
Food & Allied	269,476	7.74%	1.3%	553.9	7.14%
Misc	229,344	6.59%	0.5%	575.4	7.42%
Textile	113,023	3.25%	1.1%	731.8	9.43%
NBFI	102,803	2.95%	3.4%	405.5	5.23%
Cement	96.337	2.77%	5.7%	208.7	2.69%
G. Insurance	75,268	2.16%	-0.8%	338.9	4.37%
L. Insurance	47,129	1.35%	1.5%	184.3	2.38%
Travel & Leisure	37.585	1.08%	-0.5%	267.8	3.45%
Mutual Fund	29.375	0.84%	-0.8%	210.6	2.71%
IT	24,479	0.70%	0.1%	189.7	2.45%
Tannery	22,305	0.64%	0.0%	62.0	0.80%
Paper & Printing	20,568	0.59%	0.6%	254.6	3.28%
Ceramics	17,792	0.51%	0.2%	97.5	1.26%

Ticker	Close Price (BDT)	Dally ∆ %	Turnover (BDTmn)	Volume (mn)	P/E (x)
BSC	101.10	6.98%	309.42	3.12	5.27
SEAPEARL	53.10	-2.75%	229.46	4.22	n/a
BRACBANK	63.80	1.75%	223.53	3.56	7.03
RENATA	516.90	4.64%	203.41	0.40	24.31
KBPPWBIL	121.10	0.25%	151.75	1.26	605.50
Top Gainers					
Ticker	Close Price (BDT)	Dally ∆ %	Turnover (BDTmn)	Volume (mn)	P/E (x)
KPCL	12.30	9.82%	17.33	1.42	70.96
PRIMEFIN	4.50	9.76%	2.40	0.54	n/a
MHSML	15.90	9.66%	32.19	2.05	17.04
IDLC	37.80	9.25%	140.91	3.78	7.75
SBACBANK	8.30	9.21%	37.13	4.59	14.82
Top Losers					
Ticker	Close Price (BDT)	Dally ∆ %	Turnover (BDTmn)	Volume (mn)	P/E (x)
EIL	39.50	-9.82%	77.89	1.90	34.05
SEMLLECMF	10.40	-9.57%	32.63	3.04	41.05
RAHIMTEXT	154.10	-5.05%	20.49	0.13	144.47
TAKAFULINS	33.70	-4.53%	0.51	0.02	21.06

Please see penultimate page for additional important disclosures: UCB Stock Brokerage Ltd. ("UCB") is a foreign broker-dealer unregistered in the USA. UCB research is prepared by analysts who are not registered in the USA. UCB research is distributed in the USA pursuant to Rule 15a-6 of the Securities Exchange Act of 1934 solely by Marco Polo Securities Inc., an SEC registered and FINRA-member broker-dealer.



# **Daily Market Review**

Market closed positive

RENATA

Company achieves EU GMP approval for potent product facility
The company has informed that it has achieves European Union
Good Manufacturing Practice (EU GMP) approval for its Mirpour
potent product facility. This marks a historic milestone as the firstever EU GMP approved potent product facility in Bangladesh. The
approval was granted following an inspection conducted by the
German Regulatory Authority (Competent Authority of SaxonyAnhalt or Landesverwaltungsamt Sachsen-Anhalt). The
comprehensive certification details are publicily available on the
Eudra GMP website. This approval joins the company's existing
repertoire of regulatory approvals for multiple facilities from
Stringent Regulatory Authorities including UK-MHRA, US-FDA,
PIC/S, WHO-PQ, Health Canada, TGA and ANVISA.

MERCANBANK
Q2 Financials
Consolidated EPS was Tk. 0.98 for April-June 2025 as against Tk.
1.25 for April-June 2024; Consolidated EPS was Tk. 1.82 for
January-June 2025 as against Tk. 1.98 for January-June 2024.
Consolidated MOCFPS was Tk. 3.60 for January-June 2025 as
against Tk. 7.93 for January-June 2024. Consolidated NAV per
share was Tk. 25.11 as on June 30, 2025 and Tk. 23.75 as on
December 31, 2024. Reasons for deviation: Earnings Per Share
(EPS) decreased compared to previous period due to the decrease
of Profit before provision. Net Operating Cash Flow Per Share
(NOCFPS) decreased compared to previous period due to decrease
in Cash flows from Net Operating activities.

in Cash flows from Net Operating activities.

BDFINANCE
QZ Financials
Consolidated EPS was Tk. 0.07 for April-June 2025 as against Tk. 0.13 for April-June 2024 (Consolidated EPS was Tk. 0.12 for January-June 2025 as against Tk. 0.33 for January-June 2024. Consolidated NOCFPS was Tk. (0.16) for January-June 2025 as against Tk. 0.54 for January-June 2025 as against Tk. 0.54 for January-June 2024. Consolidated NAV per share was Tk. (29.92) as on June 30, 2025 and Tk. (30.05) as on December 31, 2024. Reason for changes in EPS (Consolidated): The decrease in the company's consolidated Earnings Per Share (EPS) for the 2nd quarter of 2025 was mainly due to a decline in net interest income and investment income compared to the corresponding period of the previous year. Reason for changes in NOCFPS (Consolidated): The decline in the consolidated Net Operating Cash Flows Per Share (NOCFPS) is primarily attributable to a reduction in net interest received, Jower income from investments, and net repayments of borrowings, compared to the corresponding period of the previous year.

Ticker	Max Price (BDT)	Min Price (BDT)	No. of Trades	Volume	Value (BDTmn)
ACFL	16.9	16.9	1	30000	0.507
AMANFEED	25.6	25.6	1	50000	1.28
ASIATICLAB	45	45	4	770100	34.654
BATBC	274.1	274.1	1	2500	0.685
BEACONPHAR	115.2	115.2	1	8700	1.002
BEXIMCO	99.4	99.4	5	25161	2.501
BRACBANK	61.5	61.5	1	302000	18.573
BSC	101	101	1	5000	0.505
BXPHARMA	98	98	2	17800	1.744
CAPMBDBLMF	10	10	1	94000	0.94
DGIC	26.8	26.6	2	82000	2.191
IFIC	6.3	6.3	1	1050000	6.615
KDSALTD	46.7	46.7	1	35050	1.637
LHB	46.6	46.6	1	10743	0.501
LOVELLO	107.1	96	2	108150	10.473
MEGHNALIFE	50.7	50.7	1	16037	0.813
MLDYEING	11.1	11.1	1	45400	0.504
QUASEMIND	39.5	39.5	1	35035	1.384
RAHIMAFOOD	111	111	1	5655	0.628
RELIANCE1	17.7	17.7	1	125000	2.212
RENATA	500	480.8	2	2040	1
SEMLLECMF	12.2	12.2	1	100000	1.22
SHEPHERD	18.5	18	6	529101	9.704
SIBL	8.7	8.7	1	60000	0.522
SQURPHARMA	208.4	208.4	1	2400	0.5
TILIL	42	42	1	17000	0.714
TOSRIFA	22	22	1	41000	0.902
UTTARABANK	21.6	21.6	1	25000	0.54
VFSTDL	8.2	8.2	1	100000	0.82



# Disclaimer

For U.S. persons only: This research report is a product of UCB Stock Brokerage Ltd. ("UCB"), a company authorized to engage in securities activities in Bangladesh, under Marco Polo Securities 15a-6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

Research reports are intended for distribution by only to "Major Institutional Investors" as defined by Rule 15a-6 (b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a-6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, UCB has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be affected through Marco Polo or another U.S. registered broker dealer.



Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by UCB Stock Brokerage Limited (UCB) with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of UCB and UCB accepts no liability whatsoever for the actions of third parties in this respect.

#### EQUITY RECOMMENDATION STRUCTURE (ABSOLUTE RATINGS)

We calculate our target price by weighting DCF, DDM, SOTP, asset-based and other relative valuation methods, and applying appropriate premiums/ discounts and/or other relevant adjustments.

Expected absolute returns are calculated as the % of difference between our target price and latest close price. Stock recommendations are based on absolute upside (downside) and have a 12-month horizon. Please note that future price fluctuations could lead to a temporary mismatch between upside/downside for a stock and our recommendation.

Recommendation Type	Holding period (if not otherwise mentioned)	Absolute Return Potential
Buy	12 Months	More than +15%
Neutral/ Hold	12 Months	Between -5% and +15%
Underweight	12 Months	Less than -5%

#### **ANALYST CERTIFICATION**

Respective analyst(s) identified in this report certifies, with respect to the companies or securities that the individual analyses, that (1) the views expressed in this report reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this report. The research analyst(s) named on this report are not registered / qualified as research analysts with FINRA.

It has not been determined in advance whether and in what intervals this document will be updated. Unless otherwise stated current prices refer to the most recent trading day's closing price.



# **Contact Us**

### Research Team

Md. Hasib Reza, CFA	Head of Research	hasib.reza@ucbstock.com.bd	+880 1755 658 997
Md. Nazmus Sakib, CFA	Deputy Head of Research	nazmus.sakib@ucbstock.com.bd	+880 1701 205 073
Anik Mahmood Ibne Anwar, CFA	Deputy Head of Research	anik.mahmood@ucbstock.com.bd	+880 1701 205 074
Fahmid Islam Sadhin	Research Associate	fahmid.islam@ucbstock.com.bd	+880 1325 086 738
Nafis Zaki	Research Associate	nafis.zaki@ucbstock.com.bd	+880 1871 891 263
Mahmudul Hasan Meraz	Research Associate	mahmudul.hasan@ucbstock.com.bd	+880 1324 719 456
Numair M N Ahmmed	Research Associate	ahmmed.numair@ucbstock.com.bd	+880 1324 719 484

# **Investment Strategist**

Syed Adnan Huda, CFA	First Vice President	adnan@ucbstock.com.bd	+880 1730 325 232
-,			

# Institutional & Foreign Trade

Tahmidur Rahman First As	ssistant Vice President	rahman.tahmidur@ucbstock.com.bd	+880 1726 995 520

# Office Premises

#### **Head Office**

#### Gulshan

Bulus Center +880 2955 8481

# **Extensions of Head Office**

<b>Dilkusha</b>	<b>Dilkusha (NIK Tower)</b>	<b>Dhanmondi</b>	<b>Nikunja</b>	<b>Mohammadpur</b>
+880 1701 205 090	+880 1701 205 000	+880 1713 205 703	+880 1701 205 013	+880 1324 243 212
<b>Bashundhara</b>	<b>Mirpur-1</b>	<b>Mirpur-12</b>	<b>Banasree</b>	<b>Uttara</b>
+880 1718 106 217	+880 1713 205 723	+880 1911 197 188	+880 1701 205 075	+880 1913 128 156

### **Branch Offices**

Chattogram	Sylhet
+880 1701 205 038	+880 1713 205 760

# **Digital Booths**

Khulna	Barishal	Cumilla	Jashore	Gazipur
+880 1717 411 466	+880 1713 205 762	+880 1324 243 163	+880 1324 243 203	+880 1324 243 165

Khatungonj	Chawkbazar	Madhobdi
+880 1713 205 742	+880 1817 206 965	+880 1324 243 156
Narayangonj		
+880 1324 243 207	+880 1324 243 198	
	+880 1713 205 742	+880 1713 205 742 +880 1817 206 965  Narayangonj Agrabad